Three Severely Ill Long COVID Patients - Three Rapid Recoveries (patient 1)
- Condition
- Long COVID
- At worst
- Severe (mostly bedbound)
- Ill for
- 1 year
- Published
- Nov 2023
Summary
This patient developed severe long COVID after a confirmed infection, unable to climb stairs or walk without severe fatigue and with neurological and cardiac symptoms, gaining only mild relief from vaccination. About a year after infection she received the casirivimab and imdevimab monoclonal antibody cocktail, after which the post says all her long COVID symptoms dissipated. She remained healthy two years later with no relapse reported.
What they credit
Credits Craniocervical surgery, Biologics & antibodies, Monoclonal antibodies (casirivimab, Pemgarda).
Similar stories
-
Monoclonal antibodies article comments (Chris)
Chris is participating in a Vanderbilt clinical trial of baricitinib for long COVID, having started the drug on October 18, 2025. He reported feeling "the best I have since I got Covid," becoming functional though still limited. As of his comment he was…
-
Monoclonal antibodies article comments
Credits monoclonal antibody. An unnamed patient was ill 4.5y with severe long COVID, improved, then relapsed. Pemgarda gives 8-10 week remission per dose.
-
Three Long-term Long COVID Patients, Three Rapid Recoveries
Pemivibart (Pemgarda), a monoclonal antibody infusion whose effect the article says typically lasts about a couple of months, was given to three long-term long COVID patients. A 70-year-old woman, sick for nearly a year, had her brain fog, breathlessness and…
-
No easy home runs: early Long COVID Paxlovid and monoclonal trials
Amy Engebretson took part in Yale's PaxLC trial of Paxlovid and has continued taking ritonavir, one of Paxlovid's components, because she says it "improved my symptoms quite a bit"; the article gives no specific dose or treatment duration for her. It does…